ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Trading 3.1% Higher – Still a Buy?

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) traded up 3.1% during trading on Thursday . The company traded as high as $52.32 and last traded at $52.09. 15,949 shares traded hands during trading, a decline of 54% from the average session volume of 34,859 shares. The stock had previously closed at $50.52.

ALPS Medical Breakthroughs ETF Stock Up 1.3%

The company’s 50 day moving average price is $53.89 and its 200-day moving average price is $51.87.

Hedge Funds Weigh In On ALPS Medical Breakthroughs ETF

Several hedge funds have recently made changes to their positions in the business. Delta Investment Management LLC acquired a new position in shares of ALPS Medical Breakthroughs ETF in the 4th quarter worth approximately $6,112,000. Bank of America Corp DE grew its stake in shares of ALPS Medical Breakthroughs ETF by 63.1% in the 1st quarter. Bank of America Corp DE now owns 98,679 shares of the company’s stock worth $5,165,000 after purchasing an additional 38,193 shares during the last quarter. LPL Financial LLC grew its stake in shares of ALPS Medical Breakthroughs ETF by 438.7% in the 4th quarter. LPL Financial LLC now owns 42,755 shares of the company’s stock worth $2,190,000 after purchasing an additional 34,819 shares during the last quarter. Griffin Asset Management Inc. grew its stake in shares of ALPS Medical Breakthroughs ETF by 1.9% in the 4th quarter. Griffin Asset Management Inc. now owns 30,699 shares of the company’s stock worth $1,572,000 after purchasing an additional 564 shares during the last quarter. Finally, Moran Wealth Management LLC grew its stake in shares of ALPS Medical Breakthroughs ETF by 39.2% in the 1st quarter. Moran Wealth Management LLC now owns 29,348 shares of the company’s stock worth $1,536,000 after purchasing an additional 8,264 shares during the last quarter.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.